Alzheimer; News from the web:
The recent FDA approval of a new medicine for Alzheimer’s has still some questions about who is eligible to get it, the costs and more. Read the article in our link for today for some insights.
Read all about it HERE
Alzheimer; News from the web:
Truly great news today, the new drug Aducanumab has been approved by the FDA for use in early Alzheimer’s cases.
The drug was developed for patients with mild cognitive impairment, not severe dementia, and intended to slow progression of Alzheimer’s disease — not just ease symptoms.
Read all about it HERE
Alzheimer; News from the web:
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer’s disease rather than relieve symptoms.
But it’s unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.
Read all about it HERE
Alzheimer; News from the web:
A new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline
There may be a trial near you check it out
Read all about it HERE
Alzheimer; News from the web:
In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.
Read all about it HERE
Alzheimer; News from the web:
Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
https://www.technologynetworks.com/
Read all about it HERE
Alzheimer; News from the web:
Listen to the podcast in our link for today to get a better appreciation of what the issues involved are.
Read all about it HERE
Alzheimer; News from the web:
Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.
Read all about it HERE
Alzheimer; News from the web:
Everyone has their eyes on this year’s flu season, which is predicted to collide with the on-going COVID-19 pandemic.
The CDC and other health agencies are already issuing strong recommendations to the public to get their flu shot as early as possible.
In addition to protecting against the flu, flu shots may also have an unexpected benefit: lowering the risk of Alzheimer’s disease.
Read all about it HERE
Alzheimer; News from the web:
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Read all about it HERE
Alzheimer; News from the web:
An interesting development is that apparently an experimental drug, aimed to help people with Alzheimer’s, could play a role in helping children with certain types of Autims. Read the full story in our link for today.
Read all about it HERE
Alzheimer; News from the web:
Clinical trials of Alzheimer’s medicines have failed frequently but now researchers believe that this may have been caused by the drugs given too late. So if they could just develop a test that would detect Alzheimer’s earlier, it would make the drugs that have failed for use later in the process, so much more productive.
Read all about it HERE
Alzheimer; News from the web:
This sounds like good news. Scientists have found a way to speed up the testing of Alzheimer’s drugs.
Alzheimer’s clinical trials may take decades, but a new discovery could cut clinical trial time down to a matter of weeks.
Read all about it HERE
Alzheimer; News from the web:
A laboratory study has found that the asthma drug salbutamol prevents the formation of tangles of fibrous protein that are a hallmark of Alzheimer’s disease. The next step will be to test the drug in animal models of the disease.
Read all about it HERE
Alzheimer; News from the web:
For this to hit the market: There are two drugs that have been developed by Salk Institute researchers to successfully treat Alzheimer’s in mice—and now, they have found that the very same drug compounds can also slow the aging process in the brains of healthy older mice.
Read all about it HERE
Alzheimer; News from the web:
Today we link to the article from Scientific American that tells the story about the reassessment of costs vs benefits for aducanumab.
Read all about it HERE
Alzheimer; News from the web:
Alzheimer’s disease affects some 5 million people in the United States, and as the population ages, doctors estimate those affected will more than double by 2050.
A new drug might offer new hope, WOWT reported.
Read all about it HERE
Alzheimer; News from the web:
Despite many promising leads, more than 120 drug treatments for Alzheimer’s disease have failed. But Cambridge-based biotech company Biogen revived hope on Tuesday with its announcement that it would seek Food and Drug Administration approval for a drug it abandoned earlier this year.
Read all about it HERE
Alzheimer; News from the web:
The biotech world went into a full-on frenzy Tuesday when drug giant Biogen dropped this whopper: The company is reviving its Alzheimer’s drug hopeful, aducanumab, after leaving it for dead all the way back in March. In fact, it’s marching forward with a Food and Drug Administration (FDA) application to approve the drug for certain patients facing cognitive decline.
Read all about it HERE
Alzheimer; News from the web:
Read all about it HERE
Alzheimer; News from the web:
An Alzheimer’s vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday.
Read all about it HERE
Alzheimer; News from the web:
Researchers have found that nilvadipine, a drug that doctors regularly use to treat hypertension, may help people with Alzheimer’s disease by increasing blood flow to the brain.
Read all about it HERE
Alzheimer; News from the web:
A cure for Alzheimer’s Disease does not exist just yet, but researchers at the University of New Mexico (UNM) are one step closer to finding one.
Read all about it HERE
Alzheimer; News from the web:
Treatment with blood pressure medication can improve blood flow to a key brain region in people with Alzheimer’s disease, a small clinical trial has found.
Read all about it HERE
Alzheimer; News from the web:
Alzheimer’s drugs cost seven times more than cancer drugs to develop
Read all about it HERE
Alzheimer; News from the web:
There are roughly 326 active, recruiting or enrolling by invitation clinical trials on the elusive disease, per clinicaltrial.gov. The U.S. last year dramatically stepped up funding for Alzheimer’s disease research, from $400 million a year to over $2 billion annually, although the Alzheimer’s Association says more is needed.
The biggest problem: Scientists still don’t know the cause of Alzheimer’s.
Read all about it HERE
Alzheimer; News from the web:
Here is a new drug that seemed effective for mice and now has been found safe for humans, so the next step it to test it on patients with Alzheimer’s. Exciting times
Read all about it HERE
Alzheimer; News from the web:
The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”
The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.
Read all about it HERE
Alzheimer; News from the web:
Check out the project in the link for today. The claim is a novel process to find a way to immunize against Alzheimer’s disease. Not sure how this low budget will win from all the billions already spent by the large pharmaceutical companies but see for yourself.
Read all about it HERE